March 18, 2019 - Karuna Announces $68 Million Series B Financing

March 13, 2019 - Karuna Bolsters Research and Development Team

March 5, 2019 - Karuna Strengthens Senior Leadership Team with Appointment of Chief Financial Officer

January 11, 2019 - A Boston biotech takes on a challenge most companies have avoided: making a better schizophrenia drug


December 10, 2018 - Karuna Pharmaceuticals to Present Results of KarXT Phase 1 Study at American College of Neuropsychopharmacology Annual Meeting

October 17, 2018 - Karuna Appoints Jeff Jonas, M.D., to Board of Directors

October 15, 2018 - Karuna Announces First Patient Dosed in Phase 2 Study of Lead Product Candidate KarXT for the Treatment of Schizophrenia

August 15, 2018 - Karuna Appoints Seasoned Biopharma Veteran Steven Paul, M.D., as Chief Executive Officer

August 2, 2018 - Karuna Completes $42 Million Series A Financing Round to Advance Selective Muscarinic Receptor Agonist Program into Phase 2 Study

June 19, 2018 - Karuna Receives $8 Million Wellcome Trust Award to Advance First-in-Class Phase 2 Clinical Program in Schizophrenia


May 19, 2017 — Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings


December 15, 2016 — Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimer's

December 5, 2016 — ACNP 55th Annual Meeting Presentation: Xanomeline Plus Trospium: A Novel Strategy to Enhance Pro-Muscarinic Efficacy and Mitigate Peripheral Side Effects

September 12, 2016 — Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate

July 29, 2016 — Karuna Pharmaceuticals Appoints Atul Pande, M.D., to Board of Directors


August 5, 2015 — Karuna Receives Wellcome Trust Award to Advance Innovative Clinical Stage Product Candidate for the Treatment of Schizophrenia